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ABSTRACT
Background: Arteriovenous fistula (AVF) is the optimal method for obtaining vascular access 
for dialysis. Measures such as systemic anticoagulation have been proposed as means of 
increasing patency rates, but not enough evidence exists to support their application. In this 
study, we evaluated the efficacy of preoperative heparin injection on the patency of AVF during 
the first 24 hours after surgery and determined whether this measure can be used to prevent early 
thrombosis of the vascular access. Methods: This study was conducted on 150 patients admitted 
to Shohada-e-Tajrish Hospital for permanent vascular access placement during 2011-2012. 
Seventy-five patients were randomly assigned to receive 100 units/kg of heparin intraoperatively 
and at 24 hours after surgery. The AVF patency rate was assessed and compared to the control 
group. Results: All 75 patients who received heparin intraoperatively had a patent AVF 24 hours 
after surgery; this showed a statistically significant difference compared to the control group, 
among which only 69 (92%) patients had a functioning AVF (P=0.028). Conclusion: Systemic 
anticoagulation with heparin can be an effective option for preventing vascular access failure. 
However, considering the contradictory data on the usefulness of heparin injection, larger trials 
are needed to evaluate efficacy and adverse effects of systemic intraoperative anticoagulation in 
patients with end-stage renal disease before qualifying it as a method for increasing AVF patency.
INTRODUCTION
Chronic kidney disease is a global health issue with increas‑
ing prevalence (1). It is defined by the presence of kidney 
damage or decreased kidney function for at least 3 months, 
irrespective of the cause (2). In advanced cases, renal 
 replacement therapies, including hemodialysis, peritoneal 
dialysis, hemofiltration, and renal transplantation, are sug‑
gested for patients as life-extending measures (3).
With the advances in the supportive treatment of chron‑
ic renal insufficiency and the increasing number of patients 
suffering from chronic kidney disease (4), vascular access 
placement surgeries, which are needed to perform dialysis, 
have become a very common surgical procedure throughout 
the world. Several vascular access techniques are available. 
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If the patient is to be on dialysis for a short time, a  double 
lumen catheter is an appropriate choice; but to obtain per‑
manent vascular access, the three available options are ar‑
teriovenous fistula (AVF), arteriovenous graft, and venous 
catheter. AVF is considered the best long-term vascular 
access for hemodialysis (5) because it provides adequate 
blood flow and lasts a long time. Moreover, despite the ob‑
served complications such as infection, pseudo‑aneurysm 
formation, hemorrhage, venous hypertension, neuropathy, 
limb ischemia, and cardiac failure (6), this technique has a 
lower complication rate compared to other types of vascu‑
lar access, making it a more suitable choice (7). Grafts are 
prone to frequent stenosis and thrombosis. Most arteriove‑
nous access failures result from endothelial cell injury, sta‑
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sis, and  hypercoagulability, the latter being a major cause 
since patients with renal failure requiring hemodialysis are 
frequently at increased risk for hypercoagulable states, mak‑
ing these patients vulnerable to thrombosis and subsequent 
access failure (8). The available options for reversing AVF 
occlusion are costly and might result in technical failure (9); 
therefore, preventing and reducing vascular access failure 
is a priority. AVF patency is affected by many factors, in‑
cluding but not limited to vessel diameter, patient age, and 
concomitant vascular disorders such as diabetes (10). Use 
of adjuvant medical therapies such as intraoperative heparin 
administration (11-12), anti-platelet therapy (13-14), topi‑
cal glyceryl trinitrate injection (15), and postoperative flow 
monitoring (16) have been proposed as means of increasing 
patency rates, but not enough evidence currently exists to 
support their use, especially considering the costs and proba‑
ble side effects, such as increased risk of bleeding.
We conducted the current study to assess the effect of 
heparin on the early patency of AVF. We evaluated the effi‑
cacy of preoperative heparin injection on patency of the AVF 
during the first 24 hours after surgery and determined wheth‑
er this measure can be used to prevent early thrombosis of 
the vascular access.
METHODS
This open-label randomized controlled trial, which is regis‑
tered in the clinicaltrials.gov database (ID: NCT02493504), 
was conducted on patients admitted to Shohada-e-Tajrish 
Hospital in Tehran, Iran, for permanent vascular access 
placement. From April 2011 to September 2012, using a 
convenience sampling method, all patients referred by a 
nephrologist for AVF placement were included. Therefore, 
the need for this procedure was determined by the patients’ 
own physician, and we, the authors, did not reevaluate the 
patients. Exclusion criteria consisted of having a contraindi‑
cation for administration of anticoagulant agents and being 
candidate for arteriovenous graft or central venous catheter 
placement. A total of 174 patients were found to be eligible, 
of whom 24 were not willing to participate and withdrew 
from the study. Eventually, 150 patients were enrolled.
All patients were operated on by a single surgeon. The 
distal vascular system of the non-dominant upper extremi‑
ty (mostly the left arm) was generally used unless unfavor‑
able vasculature or previous fistula placement changed the 
preference. To assess the arterial circulation of the forearm 
and hand, radial and ulnar pulses were checked, and Allen’s 
test was performed. In cases with abnormal findings of these 
evaluations, Doppler ultrasound was done. Local anesthesia 
was induced by percutaneous injection of 4 mg/kg lidocaine 
hydrochloride 0.5% solution. The anastomosis technique 
was either end‑to‑side or side‑to‑side. Continuous sutures 
were taken using a number 6.0 prolene suture. Through a 
simple randomization method, 75 patients were assigned to 
receive 100 units/kg of intravenous heparin after dissection 
prior to anastomosis; the other 75 received no intraopera‑
tive heparin injection. Auscultation of bruit and palpation of 
thrill were used to assess AVF patency in the first 24 hours 
after AVF placement. Concurrently, patients were evaluated 
regarding early complications of surgery, including hemor‑
rhage, hematoma, and wound dehiscence.
Data were analyzed with SPSS v. 13 software using in‑
dependent sample t-tests, the chi-squared test, and Fisher’s 
exact test as needed. P values less than 0.05 was considered 
statistically significant.
Patient enrollment was voluntary, and no costs were im‑
posed on the patients. Study protocol was in accordance with 
the 1975 Declaration of Helsinki, and written informed con‑
sent was obtained from the included patients.
RESULTS
Mean age was 54.63±19.71 for patients in the control group 
and 52.37±15.78 years for patients in the intervention group. 
Fifty-four patients (66.7%) in the control group and 50 pa‑
tients (72%) in the intervention group were men. In the 
control group, 50.7% of patients had diabetes, whereas in 
the intervention 37.3% of patients had diabetes. In the con‑
trol group, 77.3% of patients had a history of hypertension, 
whereas 70.7% of patients in the intervention group had a 
history of hypertension. In the control group, 9.3% of patients 
were cigarette smokers, whereas 20% of patients in the in‑
tervention arm were cigarette smokers. In the control group, 
9.3% of patients had undergone previous fistula placement, 
whereas 18% of patients in the intervention group had un‑
dergone previous fistula placement. As for the anastomosis 
technique, 10.7% of patients in the control group and 21.3% 
of patients in the intervention arm were end‑to‑side, with the 
rest being side-to-side (Table 1). No significant differences 
were observed between the two groups regarding the men‑
tioned variables (P>0.05). Moreover, none of the patients 
presented with bleeding, hematoma, or wound dehiscence.
Table 1. Correlation between evaluated variables and in‑
travenous heparin administration
All 75 patients who had received heparin intraoperative‑
ly had a patent AVF 24 hours after surgery, which showed 
a statistically significant difference compared to the control 
group, among which only 69 (92%) of patients had a func‑
tioning AVF (P=0.028) (Table 1). Since no patients in the 
intervention group presented with AVF failure, the odds ratio 
could not be calculated to evaluate the correlation between 
heparin administration and AVF patency.
DISCUSSION
AVF is the optimal method of obtaining vascular access for di‑
alysis, and measures to increase patency rates of AVF have be‑
come a subject of interest for researchers. One of the proposed 
techniques to reduce vascular access failure is systemic anti‑
coagulation. Unfortunately, there are not enough studies avail‑
able on the efficacy of heparin in preventing access occlusion.
In our study, we evaluated the effect of intraoperatively 
administered heparin on the patency of AVF 24 hours after 
surgery. Our results showed a statistically significant differ‑
ence between the patency rates of AVF in patients who had 
received 7500 units of heparin prior to anastomosis (100% 
patency in the intervention group vs. 92% patency in the 
control group) (P= 0.028).
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Our results agreed with several other studies on the same 
subject. In 2007, Sharatkumar et al. examined the efficacy 
of a specific thromboprophylaxis protocol on the patency of 
AVF in 22 pediatric patients in Michigan (17). The protocol 
consisted of 5-10 units/kg/hr unfractionated heparin infusion 
postoperatively, followed by subcutaneous low-molecu‑
lar-weight heparin until AVF was matured. They observed 
that the incidence of thrombosis was lower in patients who 
received the protocol (12.5% compared to 83%; P<0.05) and 
concluded that anticoagulation can be considered feasible in 
preventing early thrombosis at AVF (17).
In another study by Ravari et al. (11), which was con‑
ducted on 198 end-stage renal disease patients in Iran in 
2005, the patency rate 2 weeks after surgery showed a sta‑
tistically significant difference between those who received 
heparin and those who did not (85% vs. 74%; P=0.046%). 
Therefore, they concluded by recommending the routine use 
of intraoperative heparin in AVF operations (11).
However, other trials have yielded different results re‑
garding the efficacy of heparin administration on access pa‑
tency. In their 2008 study conducted on 50 patients in Nepal, 
Bhomi et al. observed that the patency rate 6 weeks after 
surgery was 96% for patients who received 5000 units of 
heparin and 92% for those who did not (18). They concluded 
that systemic coagulation during vascular access surgery of‑
fers no benefit in terms of primary patency, while increasing 
the risk of hemorrhagic complications.
A 2008 study by D’Ayala et al. (19), conducted on 
115 patients in New York, evaluated the efficacy of systemic 
anticoagulation on patency of both AVF and arteriovenous 
grafts. According to the results of this study, at 1 month and 
3 months after surgery, the patency of the vascular access 
did not increase significantly in patients who had received 
heparin (84% vs. 86% at 1 month and 68% for both groups 
at 3 months), while perioperative bleeding complications did 
increase (P=0.008) (19).
In 2010, Wang et al. published the results of a dou‑
ble-blind randomized controlled trial, which had been con‑
ducted on 48 patients undergoing AVF creation (20). Their 
results suggested that intraoperative administration of hep‑
arin had no statistically significant effect on patency rates 
(92% vs. 86%; P=0.65) or postoperative bleeding complica‑
tions (P=0.61) (20).
In 2011, Charlton-Ouw et al. compared the patency of AVF 
with heparin-bonded and conventional grafts (21). Evaluating 
the outcomes of 64 brachiocephalic fistula, 21 brachioaxil‑
lary heparin-bonded, and 21 brachioaxillary conventional AV 
grafts, they found the 1‑year cumulative patency rates of these 
methods to be 83%, 44%, and 67%, respectively P=0.001).
Therefore, given that no consensus has been reached on 
this matter and considering the number of conflicting trials, 
a meta‑analysis of the trials, including the present survey, is 
recommended.
This study’s limitations include lack of blinding and lack 
of assessment of AVF patency beyond 24 hours after surgery.
CONCLUSION
We found a statistically significant difference between the 
patency rates of AVF at 24 hours after surgery in patients 
who received heparin prior to anastomosis (P=0.028). Con‑
sidering the contradictory data on the usefulness of heparin 
injection and the limitations of our study, larger trials with 
different follow‑up durations are needed to evaluate the ef‑
ficacy and adverse effects of systemic intraoperative antico‑
agulation in end‑stage renal disease patients, to determine 
whether intraoperative heparin administration can be an ef‑
fective method for increasing AVF patency.
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